Improved dystrophin proteins for Duchenne muscular dystrophy
Expression of dystrophins with enhanced function
Researchers are developing stronger, safer dystrophin proteins delivered by viral and genetic tools to help people with Duchenne muscular dystrophy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11262199 on NIH RePORTER |
What this research studies
This project aims to create improved versions of the dystrophin protein that can be delivered to muscles using AAV viral vectors, antisense oligonucleotides (ASOs), and gene-editing approaches. Scientists will test these enhanced dystrophins in cells and animal models to determine whether they restore muscle function more effectively and with fewer side effects. The team builds on existing micro-dystrophin gene therapies and exon-skipping ASO drugs while exploring ways to avoid genomic damage linked to some gene-editing methods. Promising lab results would support future clinical testing to evaluate safety and benefit in people with DMD.
Who could benefit from this research
Good fit: This work is aimed at people with Duchenne muscular dystrophy caused by mutations in the DMD gene who could be candidates for future gene or exon-skipping therapies.
Not a fit: People with other types of muscular dystrophy or conditions not caused by DMD gene mutations are unlikely to benefit from these specific approaches.
Why it matters
Potential benefit: If successful, this work could lead to safer, more effective treatments that improve muscle strength and slow disease progression in Duchenne muscular dystrophy.
How similar studies have performed: Similar micro-dystrophin gene therapies and several exon-skipping antisense drugs have produced encouraging clinical results and some have received FDA approval, while gene-editing approaches are newer and less proven.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Chamberlain, Jeffrey S — University of Washington
- Study coordinator: Chamberlain, Jeffrey S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.